二代测序技术在骨髓增生异常综合征诊治中的临床应用

doi:10.16150/j.1671-2870.2016.06.003

摘要/Abstract

中图分类号:

R551.3

宋陆茜, 常春康. 二代测序技术在骨髓增生异常综合征诊治中的临床应用[J]. 诊断学理论与实践, 2016, 15(06): 556-560.

[1] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Malcovati L, Papaemmanuil E, Bowen DT, et al.Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms[J]. Blood,2011,118(24):6239-6246.
[3] 张丽, 吴修进, 关蒲骏, 等. 第二代测序技术在血液系统疾病临床应用中的研究进展[J]. 中华血液学杂志,2015,36(8):716-720.
[4] Mardis ER, Ding L, Dooling DJ, el al. Recurring mutations found by sequencing an acute myeloid leukemia genome[J]. N Engl J Med,2009,361(11):1058-1066.
[5] Ley TJ, Ding L, Walter MJ, et al.DNMT3A mutations in acute myeloid leukemia[J]. N Engl J Med,2010,363(25):2424-2433.
[6] Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J]. N Engl J Med,2013,368(22):2059-2074.
[7] Nybakken GE, Bagg A.The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes[J]. J Mol Diagn,2014,16(2):145-158.
[8] Bejar R, Stevenson K, Abdel-Wahab O, et al.Clinical effect of point mutations in myelodysplastic syndromes[J]. N Engl J Med,2011,364(26):2496-2506.
[9] Haferlach T, Nagata Y, Grossmann V, et al.Landscape of genetic lesions in 944 patients with myelodysplastic syndromes[J]. Leukemia,2014,28(2):241-247.
[10] Papaemmanuil E, Cazzola M, Boultwood J, et al.Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts[J]. N Engl J Med,2011,365(15):1384-1395.
[11] Papaemmanuil E, Gerstung M, Malcovati L, et al.Clinical and biological implications of driver mutations in myelodysplastic syndromes[J]. Blood,2013,122(22):3616-3627.
[12] Walter MJ, Shen D, Shao J, et al.Clonal diversity of recurrently mutated genes in myelodysplastic syndromes[J]. Leukemia,2013,27(6):1275-1282.
[13] Yoshida K, Sanada M, Shiraishi Y, et al.Frequent pathway mutations of splicing machinery in myelodysplasia[J]. Nature,2011,478(7367):64-69.
[14] Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood,1997,89(6):2079-2088.
[15] Jaiswal S, Fontanillas P, Flannick J, et al.Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med,2014,371(26):2488-2498.
[16] Grimwade D, Vyas P, Freeman S.Assessment of minimal residual disease in acute myeloid leukemia[J]. Curr Opin Oncol,2010,22(6):656-663.
[17] Warren M, Luthra R, Yin CC, et al.Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients[J]. Mod Pathol,2012,25(10):1405-1412.
[18] Mancini M, Hasan SK, Ottone T, et al. Two novel me-thods for rapid detection and quantification of DNMT3A R882 mutations in acute myeloid leukemia[J]. J Mol Diagn,2015 Mar,17(2):179-184.
[19] Salipante SJ, Fromm JR, Shendure J, et al.Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing[J]. Mod Pathol,2014,27(11):1438-1446.
[20] Wu D, Sherwood A, Fromm JR, et al.High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia[J]. Sci Transl Med,2012,4(134):134-163.
[21] Spencer DH, Tyagi M, Vallania F, et al.Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data[J]. J Mol Diagn,2014,16(1):75-88.
[22] Spencer DH, Abel HJ, Lockwood CM, et al.Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data[J]. J Mol Diagn,2013,15(1):81-93.
[23] Peng Q, Vijaya Satya R, Lewis M, et al.Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes[J]. BMC Genomics,2015,16:589.

二代测序技术在骨髓增生异常综合征诊治中的临床应用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王柔嘉, 常春康. 调节性T细胞在骨髓增生异常综合征危险分层中的研究进展[J]. 诊断学理论与实践, 2021, 20(02): 221-224.
[2]	叶成林, 姚永华, 陈真, 贾麟. 骨髓活检塑胶包埋在以单纯血小板减少为表现的骨髓增生异常综合征诊断中的应用价值[J]. 诊断学理论与实践, 2020, 19(02): 177-181.
[3]	吴凌云, 常春康. 骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019, 18(06): 623-629.
[4]	杜云志, 冯菁华, 常春康. 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671.
[5]	宋元林, 侯东妮. 支气管扩张症患者气道、肠道微生态的研究及临床价值[J]. 诊断学理论与实践, 2019, 18(05): 503-508.
[6]	李蕾, 吴希, 许冠群, 梁茜, 戴菁, 武文漫, 丁秋兰, 王鸿利, 王学锋. 基于新一代测序技术的易栓症基因检测Panel的建立及其在中国静脉血栓患者遗传背景研究中的临床应用[J]. 诊断学理论与实践, 2019, 18(04): 394-401.
[7]	宋丹丹, 常春康, 郭娟, 许峰, 赵佑山, 吴凌云. 骨髓增生异常综合征患者骨髓巨噬细胞百分比异常及其意义[J]. 诊断学理论与实践, 2018, 17(04): 439-443.
[8]	冯国栋, 贺旻, 汪昕. 二代测序技术在诊断神经系统感染性疾病中的应用[J]. 诊断学理论与实践, 2018, 17(04): 391-395.
[9]	师蕾, 常春康. 间充质干细胞在骨髓增生异常综合征发病机制中的研究进展[J]. 诊断学理论与实践, 2018, 17(01): 123-126.
[10]	陈冰, 眭竫旎. 急性髓系白血病微小残留病监测方式的展望[J]. 诊断学理论与实践, 2017, 16(01): 17-26.
[11]	肖志坚. 骨髓增生异常综合征的诊断[J]. 诊断学理论与实践, 2016, 15(06): 545-549.
[12]	赵智刚, 王金焕. 骨髓微环境调控骨髓增生异常综合征的作用及相关机制[J]. 诊断学理论与实践, 2016, 15(06): 550-555.
[13]	肖超, 常春康. 骨髓增生异常综合征的铁过载诊断和铁螯合治疗[J]. 诊断学理论与实践, 2016, 15(06): 561-566.
[14]	杨丽艳, 王化泉. 血小板生成素受体激动剂的作用机制及其在骨髓增生异常综合征治疗中的应用[J]. 诊断学理论与实践, 2016, 15(06): 567-572.
[15]	任艳玲, 佟红艳. 骨髓增生异常综合征常用药物治疗的机制[J]. 诊断学理论与实践, 2016, 15(06): 573-577.